Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda Pharmaceutical Company Limited Provides Dividend Guidance for the Second Quarter of Fiscal 2022 and Full Year Ending March 31, 2022

07/30/2021 | 02:00am EDT

Takeda Pharmaceutical Company Limited provided dividend guidance for the second quarter of fiscal 2022 and full year ending March 31, 2022. For the quarter, the company expects dividend of ¥90.00 per share. For the year ending March 31, 2022, the company expects dividend of ¥90.00 per share.


ę S&P Capital IQ 2021
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
04:03aTakeda Pharmaceutical Commences Construction on Zero-Emissions Building in Singapore fo..
MT
03:22aTAKEDA PHARMACEUTICAL : WFP and Takeda deepen partnership in West Africa to strengthen hea..
AQ
09/22TAKEDA PHARMACEUTICAL : Breaks Ground on its First Zero Energy Building in Singapore
PU
09/22TAKEDA PHARMACEUTICAL : WFP and Takeda deepen partnership in West Africa to strengthen hea..
AQ
09/22TAKEDA PHARMACEUTICAL : Selects Four New Partners for Annual Global Corporate Social Respo..
BU
09/21MIRUM PHARMACEUTICALS : Partners With Takeda Over Developing, Commercializing Liver Diseas..
MT
09/21TAKEDA PHARMACEUTICAL : Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Ag..
BU
09/21Mirum Pharmaceuticals, Inc and Takeda Pharmaceutical Company Limited Enter into Exclusi..
CI
09/21Mirum Inks Japan License for Maralixibat With Takeda
DJ
09/16TAKEDA PHARMACEUTICAL : Continues to Advance Growth Strategy with Sale Of Non-Core Assets ..
PU
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2022 3 387 B 30 696 M 30 696 M
Net income 2022 253 B 2 296 M 2 296 M
Net Debt 2022 3 472 B 31 474 M 31 474 M
P/E ratio 2022 23,4x
Yield 2022 4,81%
Capitalization 5 881 B 53 383 M 53 308 M
EV / Sales 2022 2,76x
EV / Sales 2023 2,63x
Nbr of Employees 47 099
Free-Float 99,3%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | 4502 | JP3463000004 | MarketScreener
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 3 740,00 JPY
Average target price 4 844,67 JPY
Spread / Average Target 29,5%
EPS Revisions
Managers and Directors
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-0.40%53 671
JOHNSON & JOHNSON4.16%431 543
ROCHE HOLDING AG10.05%322 644
PFIZER, INC.19.32%246 414
NOVO NORDISK A/S50.62%232 291
ELI LILLY AND COMPANY35.22%206 972